ArticleJournal of neuro-oncology2025
Clinical characteristics and pathological features of growth hormone-secreting pituitary adenoma combined with hyperprolactinemia.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Disentangling secretory ambiguity and the limitations of classical thresholds in defining prolactinomas.Pituitary · 2026Article
- Mammosomatotroph pituitary neuroendocrine tumour in a 7-year-old boy: case report.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Article
- Prevalence and evolution of hypertension in a large Iberian cohort of patients with acromegaly.Pituitary · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLarge-scale reports on growth hormone-secreting pituitary adenomas (GHPA) with hyperprolactinemia (HPRL) remain limited. The relationship between clinical characteristics and pathological subtypes of GHPA patients, based on the 2022 classification of pituitary neuroendocrine tumors (PitNET), has rarely been elucidated. This study aims to enhance the understanding of clinicopathological features in GHPA and clarify differences between patients with and without HPRL.
methodsWe retrospectively collected the clinical data of 810 patients diagnosed with GHPA. The clinical and pathological characteristics were compared between the HPRL and non-HPRL groups. Patients were categorized according to 2022 pathological classification and their differences were compared.
resultsCompared to the non-HPRL group, the HPRL group exhibited more visual acuity/field impairment and galactorrhea and had higher GH levels. The tumor volume (TV) in the HPRL group was significantly larger, with more severe cavernous sinus invasion and optic chiasm compression, and a higher proportion of mammosomatotroph PitNETs. The most common pathological types of GHPA included sparsely granulated somatotroph PitNETs (46.19%), mammosomatotroph PitNETs (17.37%), and plurihormonal PitNETs (17.80%). Patients with immature PIT-1 lineage PitNETs had the lowest biochemical remission rate and highest tumor residual/recurrence rate.
conclusionThe symptoms of galactorrhea and visual acuity/field impairment contribute to early diagnosis in GHPA patients with HPRL. Although TV is larger and invasiveness is greater, HPRL does not significantly affect the biochemical remission rate. Nearly half of GHPA cases are sparsely granulated somatotroph PitNETs, which are often associated with poor tumor outcomes, highlighting the critical role of pathological type in predicting clinical prognosis.
Indexed as
Identifiers
40266500What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.